Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Antirheumatic Drugs

被引：0

作者：

Philip, Mease ^{[1
,2
]}

Apinya, Lertratanakul ^{[3
]}

Bruce, Strober ^{[4
]}

Shigeyoshi, Tsuji ^{[5
]}

Pascal, Richette ^{[6
]}

Charlie, Lovan ^{[3
]}

Dai, Feng ^{[3
]}

Jaclyn, Anderson K. ^{[3
]}

Filip, van den Bosch ^{[7
]}

机构：

[1] Swedish Med Ctr, Dept Rheumatol, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] AbbVie Inc, N Chicago, IL USA

[4] Yale Univ, Sch Med, New Haven & Cent Connecticut Dermatol, 333 Cedar St, Cromwell, CT USA

[5] Osaka Minami Med Ctr, Natl Hosp Org, Dept Orthopaed Rheumatol, Osaka, Japan

[6] Lariboisiere Hosp, Dept Rheumatol, Paris, France

[7] Ghent Univ Hosp, Dept Internal Med, Ghent, Belgium

来源：

SWISS MEDICAL WEEKLY | 2021年 / 151卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P 26

引用

页码：S24 / S24

页数：1

共 50 条

[1] Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs
Mease, Philip
Lertratanakul, Apinya
Strober, Bruce
Tsuji, Shigeyoshi
Richette, Pascal
Lovan, Charlie
Feng, Dai
Anderson, Jaclyn K.
Van den Bosch, Filip
[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
[2] EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Mease, P. J.
Lertratanakul, A.
Strober, B.
Tsuji, S.
Richette, P.
Lovan, C.
Feng, D.
Anderson, J.
Van den Bosch, F.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 788 - 789
[3] Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
Nash, Peter
Richette, Pascal
Gossec, Laure
Marchesoni, Antonio
Ritchlin, Christopher
Kato, Koji
McDearmon-Blondell, Erin L.
Lesser, Elizabeth
McCaskill, Reva
Feng, Dai
Anderson, Jaclyn K.
Ruderman, Eric M.
[J]. RHEUMATOLOGY, 2022, 61 (08) : 3257 - 3268
[4] Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis
Marguerie, L
Flipo, RM
Grardel, B
Beaurain, D
Duquesnoy, B
Delcambre, B
[J]. JOINT BONE SPINE, 2002, 69 (03) : 275 - 281
[5] An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis
So, Anthony
Inman, Robert Davies
[J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2018, 32 (03): : 453 - 471
[6] Predictors of effectiveness of biologic disease-modifying antirheumatic drugs (bDMARD) in the treatment of psoriatic arthritis
Brandao, Natalia Dias
Morgado, Marina
Oliveira, Gerusa A.
Acurcio, Francisco de Assis
Guerra Junior, Augusto Afonso
Alvares-Teodoro, Juliana
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 170 - 171
[7] BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PSORIATIC ARTHRITIS: A REAL-WORLD COHORT OF 439 PATIENTS
Letarouilly, J-G
Salmon, J. -H.
Coquerelle, P.
Goeb, V.
Guyot, M. -H.
Houvenagel, E.
Maury, F.
Marguerie, L.
Morel, G.
Baudens, G.
Solau-Gervais, E.
Ramdane, N.
Flipo, R. -M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 373 - 373
[8] Cost-Utility Analysis of Biologic Disease-Modifying Antirheumatic Drugs for Patients With Psoriatic Arthritis in Thailand
Dilokthornsakul, Piyameth
Sawangjit, Ratree
Osiri, Manathip
Chiowchanwisawakit, Praveena
Louthrenoo, Worawit
Permsuwan, Unchalee
[J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 34 : 40 - 47
[9] LONG-TERM SAFETY AND EFFICACY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS BY PRIOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG EXPOSURE
Gladman, D. D.
Dougados, M.
Marzo-Ortega, H.
Cadatal, M. J.
Kinch, C.
Nash, P.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1140 - 1141
[10] Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review
Kingsley, Gabrielle H.
Scott, David L.
[J]. PSORIASIS-TARGETS AND THERAPY, 2015, 5 : 71 - 81

← 1 2 3 4 5 →